|Diagram of a thrombus (blood clot) that has blocked a blood vessel valve|
A thrombus, colloquially called a blood clot, is the final product of the blood coagulation step in hemostasis. There are two components to a thrombus: aggregated platelets and red blood cells that form a plug, and a mesh of cross-linked fibrin protein. The substance making up a thrombus is sometimes called cruor. A thrombus is a healthy response to injury intended to prevent bleeding, but can be harmful in thrombosis, when clots obstruct blood flow through healthy blood vessels.
Mural thrombi are thrombi that adhere to the wall of a blood vessel. They occur in large vessels such as the heart and aorta, and can restrict blood flow but usually do not block it entirely. They appear grey-red with alternating light and dark lines (known as lines of Zahn) which represent bands of fibrin (lighter) with entrapped white blood cells and red blood cells (darker).
- Endothelial injury: Injury to the endothelial causing platelet activation and aggregation
- Stasis: Blood stasis promotes greater contact between platelets/coagulative factors with vascular endothelium.
- Hypercoagulability (also called thrombophilia; any disorder of the blood that predisposes to thrombosis)
Disseminated intravascular coagulation (DIC) involves widespread microthrombi formation throughout the majority of the blood vessels. This is due to excessive consumption of coagulation factors and subsequent activation of fibrinolysis using all of the body's available platelets and clotting factors. The end result is hemorrhaging and ischaemic necrosis of tissue/organs. Causes are septicaemia, acute leukaemia, shock, snake bites, fat emboli from broken bones, or other severe traumas. DIC may also be seen in pregnant females. Treatment involves the use of fresh frozen plasma to restore the level of clotting factors in the blood, as well as platelets and heparin to prevent further thrombi formation.
Thrombi are classified in three major groups depending on the relative amount of platelets and red blood cells (RBCs). The three major groups are:
- White thrombi (characterized by predominance of platelets)
- Red thrombi (characterized by predominance of red blood cells)
- Mixed thrombi (with features of both white and red thrombi - an intermediate).
A thrombus occurs when the hemostatic process, which normally occurs in response to injury, becomes activated in an uninjured or slightly injured vessel. A thrombus in a large blood vessel will decrease blood flow through that vessel (termed a mural thrombus). In a small blood vessel, blood flow may be completely cut off (termed an occlusive thrombus), resulting in death of tissue supplied by that vessel. If a thrombus dislodges and becomes free-floating, it is considered an embolus.
Some of the conditions which increase the risk of blood clots developing include atrial fibrillation (a form of cardiac arrhythmia), heart valve replacement, a recent heart attack (also known as a myocardial infarction), extended periods of inactivity (see deep venous thrombosis), and genetic or disease-related deficiencies in the blood's clotting abilities.
Platelet activation can occur through different mechanisms such as a vessel wall breach that exposes collagen, or tissue factor encryption.[clarification needed] The platelet activation causes a cascade of further platelet activation, eventually causing the formation of the thrombus. This process is regulated through thromboregulation.
Prevention and treatment
Blood clot prevention and treatment reduce the risk of stroke, heart attack and pulmonary embolism. Heparin and warfarin are used to inhibit the formation and growth of existing thrombi, with the former used for acute anticoagulation while the latter is used for long-term anticoagulation. The mechanism of action of heparin and warfarin are different as they work on different pathways of the coagulation cascade. Heparin works by binding to and activating the enzyme inhibitor antithrombin III, an enzyme that acts by inactivating thrombin and factor Xa. In contrast, warfarin works by inhibiting vitamin K epoxide reductase, an enzyme needed to synthesize vitamin K dependent clotting factors II, VII, IX, and X. Bleeding time with heparin and warfarin therapy can be measured with the partial thromboplastin time (PTT) and prothrombin time (PT), respectively.
Some treatments have been derived from bacteria. One drug is streptokinase, which is an enzyme secreted by several streptococcal bacteria. This drug is administered intravenously and can be used to dissolve blood clots in coronary vessels. However, streptokinase is nonspecific and can digest almost any protein, which can lead to many secondary problems. Another clot-dissolving enzyme that works faster and is more specific is tissue plasminogen activator (tPA). This drug is made by transgenic bacteria and it converts plasminogen into the clot-dissolving enzyme, plasmin. There are also some anticoagulants that come from animals that work by dissolving fibrin. For example, Haementeria ghilianii, an Amazon leech, produces an enzyme called hementin from its salivary glands. As of 2012[update], this enzyme has been successfully produced by genetically engineered bacteria and is administered to cardiac patients.
More recent research indicates that tPA could have toxic effects in the central nervous system. In cases of severe stroke, tPA can cross the blood-brain barrier and enter interstitial fluid, where it then increases excitotoxicity, potentially affecting permeability of the blood-brain barrier, and may even cause cerebral hemorrhaging.
Thrombus formation can have one of four outcomes: propagation, embolization, dissolution, and organization and recanalization.
- Propagation of a thrombus occurs towards the direction of the heart and involves the accumulation of additional platelets and fibrin. This means that it is anterograde in veins or retrograde in arteries.
- Embolization occurs when the thrombus breaks free from the vascular wall and becomes mobile, thereby traveling to other sites in the vasculature. A venous embolus (mostly from deep vein thrombosis in the lower limbs) will travel through the systemic circulation, reach the right side of the heart, and travel through the pulmonary artery resulting in a pulmonary embolism. Arterial thrombosis resulting from hypertension or atherosclerosis can become mobile and the resulting emboli can occlude any artery or arteriole downstream of the thrombus formation. This means that cerebral stroke, myocardial infarction, or any other organ can be affected.
- Dissolution occurs when the fibrinolytic mechanisms break up the thrombus and blood flow is restored to the vessel. This may be aided by fibrinolytic drugs such as Tissue Plasminogen Activator (tPA) in instances of coronary artery occlusion. The best response to fibrinolytic drugs is within a couple of hours, before the fibrin meshwork of the thrombus has been fully developed.
- Organization and recanalization involves the ingrowth of smooth muscle cells, fibroblasts and endothelium into the fibrin-rich thrombus. If recanalization proceeds it provides capillary-sized channels through the thrombus for continuity of blood flow through the entire thrombus but may not restore sufficient blood flow for the metabolic needs of the downstream tissue.
- Thrombolysis ("destruction of clot")
- Thrombogenicity (the tendency to clot)
- National Blood Clot Alliance
- Prothrombin time
- Robbins and Cotran pathologic basis of disease. Kumar, Vinay, 1944-, Abbas, Abul K.,, Aster, Jon C.,, Perkins, James A., (Ninth ed.). Philadelphia, PA. ISBN 9781455726134. OCLC 879416939.
- "Venous thromboembolism (VTE) | McMaster Pathophysiology Review". www.pathophys.org. Retrieved 2018-11-03.
- "White Thrombi". Bayer. Retrieved 27 October 2015.
- Furie, Bruce; Furie, Barbara (2008). "Mechanisms of Thrombus Formation". The New England Journal of Medicine. 359 (9): 938–49. doi:10.1056/NEJMra0801082. PMID 18753650.
- Harter, K.; Levine, M.; Henderson, S. O. (2015). "Anticoagulation Drug Therapy: A Review". The Western Journal of Emergency Medicine. 16 (1): 11–17. doi:10.5811/westjem.2014.12.22933. PMC 4307693. PMID 25671002.
- Whalen, Karen; Finkel, Richard S.; Panavelil, Thomas A. (2014). Pharmacology. Whalen, Karen,, Finkel, Richard (Richard S.),, Panavelil, Thomas A. (Sixth ed.). Philadelphia. ISBN 9781451191776. OCLC 881019575.
- Gurewich, V. (2016). "Therapeutic Fibrinolysis: How Efficacy and Safety Can be Improved". Journal of the American College of Cardiology. 68 (19): 2099–2106. doi:10.1016/j.jacc.2016.07.780. PMID 27810050.
- Saladin, Kenneth S. (2012). Anatomy & Physiology: The Unity of Form and Function (6th ed.). New York, NY: McGraw-Hill. p. 710. ISBN 978-0-07-337825-1.
- Budzynski, A. Z. (1991). "Interaction of hementin with fibrinogen and fibrin". Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis. 2 (1): 149–52. PMID 1772982.
- Fredriksson, L.; Lawrence, D. A.; Medcalf, R. L. (2016). "TPA modulation of the blood-brain barrier: A unifying explanation for the pleiotropic effects of tPA in the CNS?". Seminars in Thrombosis and Hemostasis. 43 (2): 154–168. doi:10.1055/s-0036-1586229. PMC 5848490. PMID 27677179.
- Medcalf, R. (2011). "Plasminogen activation-based thrombolysis for ischaemic stroke: the diversity of targets may demand new approaches". Current Drug Targets. 12 (12): 1772–1781. doi:10.2174/138945011797635885.
- Kumar, Vinay; et al. (2007). Robbins Basic Pathology (8th ed.). Philadelphia: Saunders/Elsevier. ISBN 978-1-4160-2973-1.
|Look up thrombus or clot in Wiktionary, the free dictionary.|
- Treatment and Symptoms of Blood Clots -- MDhealthnetwork.org, Medical Information Resource, 1999
- North American Thrombosis Forum - NATF is a nonprofit organization dedicated to promoting thrombosis research, prevention and education, public policy, and advocacy outreach.
- Muscle Relaxing Drugs Can Reduce Lethal Blood Clots
- Air Pollution Triggers Blood Clots - US Study.
- The National Alliance for Thrombosis and Thrombophilia - has extensive stories from patients and family members on living with Thrombosis and Thrombophilia, assembled frequently asked questions and created publications addressing specific blood clot issues.